Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b20bf4e7acb6371d23d34aa573c85847 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9d6f7da1e425c8a3ef1da21e08f4c196 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e65bbe180834339727074e7c621776eb |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y204-02001 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2799-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2799-022 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2799-027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7076 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-45 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P17-182 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-1077 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-43 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
filingDate |
2016-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4d11fc41460d34bc16ee5bd21ad863b4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_01bf265b13d62352960c9b9292eac7aa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96ae166747c02d62a478dab89b0c4bbd |
publicationDate |
2016-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
AU-2016231630-A1 |
titleOfInvention |
Purine nucleoside phosphorylase as enzymatic activator of nucleoside prodrugs |
abstract |
[0102] A process for inhibiting a mammalian cancerous cell or virally infected cell includes providing a tail mutant purine nucleoside phosphorylase enzyme in proximity to the mammalian cancerous cell or the virally infected cell and exposing the enzyme to a purine nucleoside phosphorylase enzyme cleavable substrate to yield a cytotoxic purine analog. The process includes introducing to the cell a vector containing the phosphorylase enzyme, or a DNA sequence coding for the same and delivering to the cell an effective amount of the substrate such as 9-( -D-arabinofuranosyl)-2-fluoroadenine (F-araA). |
priorityDate |
2008-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |